Lyell Immunopharma, Inc. (LYEL): Cash & Equivalents
$60.18M
As of 2025-12-31
$72.98M
As of 2026-06-30
-21.3%
3-year compound annual growth
-15.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $60.18M | -43.0% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $105.60M | -27.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $145.65M | +17.9% | 2026-03-12, Balance as of period end |
| 2022-12-31 | $123.55M | -58.0% | 2025-03-11, Balance as of period end |
| 2021-12-31 | $293.83M | +109.3% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $140.41M | +45.2% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $96.67M | n/a | 2022-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $60.18M | -43.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $58.7K | -9.5% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $3.0K | -99.8% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $43.76M | +18.5% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $5.89M | -33.5% |
| Lunai Bioworks Inc. (LNAI) | 2026-06-30 | $1.71M | n/m |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $1.95M | -58.2% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $15.86M | -88.2% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $38.34M | -51.0% |
Compare LYEL, NTHI, IBO, ALT side by side · Screen every company in Pharmaceutical Preparations ↗